BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).

Type 1 diabetes occurs when the immune system attacks pancreatic beta cells. Type 2 diabetes happens when the body cannot use insulin effectively. The two types differ in symptoms, causes ...

Through comparative transcriptome analysis, Professor Kai-Chien Yang's group identified the adherens junction protein N-Cadherin as a key regulator of CM proliferation and renewal. Its expression ...

Body Dimensions 145 x 70.4 x 8.6 mm (5.71 x 2.77 x 0.34 in) ...

followed by overnight incubation at 4°C with primary antibodies against GREM1 (1:1000, Affinity), E-cadherin (1:20000, Proteintech), N-cadherin (1:3000, Proteintech), Vimentin (1:50000, Proteintech), ...

Background: Metastasis is the primary cause of cancer deaths, warranting further investigation. This study assessed microRNA-153 (miR-153) expression in bladder cancer tissues and investigated the ...

Here we show that the cell–cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during Schwann cell (SC) collective migration, which is required for peripheral nerve ...

Here, we show that coordinated activity of a type I cadherin (N-cadherin) and type II cadherins (Cadherin-6, -9, and -10) is required in both MNs and Dbx1-derived neurons to generate robust ...